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We characterized 97 non-O157 Shiga toxin (stx)–pro-
ducing Escherichia coli strains isolated from human patients 
during 2000–2009 from the national reference laboratory 
in Switzerland. These strains belonged to 40 O:H sero-
types; 4 serotypes (O26:H11/H–, O103:H2, O121:H19, and 
O145:H28/H–) accounted for 46.4% of the strains. Nonbloody 
diarrhea was reported by 23.2% of the patients, bloody diar-
rhea by 56.8%. Hemolytic uremic syndrome developed in 
40.0% of patients; serotype O26:H11/H– was most often as-
sociated with this syndrome. Forty-fi ve (46.4%) strains car-
ried stx2 genes only, 36 strains (37.1%) carried stx1, and 
16 (16.5%) strains carried stx1 and stx2. Genes encoding 
enterohemolysin and intimin were detected in 75.3% and 
70.1% of the strains, respectively. Resistance to >1 antimi-
crobial agent was present in 25 isolates. High genetic diver-
sity within strains indicates that non-O157 stx–producing E. 
coli infections in Switzerland most often occurred as single 
cases.
Shiga toxin (stx)–producing Escherichia coli (STEC) is among the most common causes of food-borne dis-
eases (1). This organism is responsible for several human 
gastrointestinal illnesses, including nonbloody or bloody 
diarrhea. Especially in children, these diseases may be af-
fected by neurologic and renal complications, including 
hemolytic uremic syndrome (HUS). Most outbreaks and 
sporadic cases of bloody diarrhea and HUS have been at-
tributed to strains of STEC serotype O157:H7. However, 
in Europe and recently in the United States, the role of 
non-O157 STEC strains (e.g., O26:H11/H–, O91:H21/H–, 
O103:H2, O111:H–, O113:H21, O121:H19, O128:H2/H–, 
and O145:H28/H–) as causes of HUS, bloody diarrhea, and 
other gastrointestinal illnesses is being increasingly recog-
nized (1).
The common feature and main virulence factor of 
STEC is production of stx1 or stx2 proteins. Human viru-
lent STEC strains often may also contain other virulence 
factors such as intimin (eae), a protein essential for the in-
timate attachment and the formation of attaching and effac-
ing lesions on gastrointestinal epithelial cells, and E. coli 
hemolysin (ehxA) (2).
Little data are available for clinical non-O157 STEC 
infections in humans, including those in Switzerland, a 
country with a small but disproportionately high popula-
tion of travelers. Therefore, we characterized all non-O157 
STEC strains collected by the Swiss National Centre for 
Enteropathogenic Bacteria (Zurich, Switzerland) during 
2000–2009, characterized these strains according to clini-
cal and anamnestic data, and compared these results with 
data from other countries in Europe and the United States.
Materials and Methods
Strains
A total of 97 non-O157 STEC strains obtained from the 
Swiss National Centre for Enteropathogenic Bacteria were 
characterized. Strains were isolated during 2000–2009 from 
fecal samples of human patients with a reasonable clinical 
suspicion of infection with STEC. Samples sent to the Cen-
tre from hospitals or private practitioners are representative 
for Switzerland and the period screened.
Serotyping
STEC isolates were serotyped by using O (O1–O186)–
specifi c and H (H1–H56)–specifi c rabbit antiserum pro-
duced at the Federal Institute for Risk Assessment (Ber-
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lin, Germany). Nonmotile strains were investigated with 
respect to their fl agellar genotypes by using PCR and HhaI 
digestion of PCR products as described (3).
Strain Characterization
Fermentation of sorbitol was tested by using sorbitol 
MacConkey agar (Oxoid Ltd., Basingstoke, UK). PCRs 
targeting the stx1 and stx2 (4,5) eae (6), and ehxA (7) genes 
were performed as described.
Genotyping
Pulsed-fi eld gel electrophoresis (PFGE) was performed 
according to the PulseNet protocol (Centers for Disease 
Control and Prevention, Atlanta, GA, USA) (8) and by us-
ing restriction enzyme XbaI and the CHEF-DR III system 
(Bio-Rad, Hercules, CA, USA). Pulse times were ramped 
from 5 to 50 sec for 19 h at an angle of 120°. Salmonel-
la enterica serovar Braenderup strain H9812 (BAA 664; 
American Type Culture Collection, Manassas, VA, USA) 
was used as a reference. GelCompar II software (Applied 
Maths NV, Sint-Martens-Latem, Belgium) was used for 
pattern comparison. PFGE patterns were considered clon-
ally related if they had a similarity coeffi cient >80% (Dice 
similarity index and unweighted pair-group with arithmetic 
mean method).
Antimicrobial Drug Susceptibility Testing
Strains were tested for antimicrobial drug resistance 
by the disk-diffusion method according to protocols of the 
Clinical and Laboratory Standards Institute (9). The panel 
of antimicrobial drug disks (Becton Dickinson, Sparks 
Glencoe, MD, USA) used contained ampicillin, amoxi-
cillin/clavulanic acid, ceftazidime, cefalothin, ciprofl oxa-
cin, cefpodoxime, cefotaxime, cefuroxime, cefepime, ce-
foxitin, gentamicin, and tetracycline. E. coli strain 25922 
(American Type Culture Collection) was used as a quality 
control.
Results
Strains
The 97 strains were isolated from 95 patients. Two 
STEC strains (968–03I and 968–03II; 2244–08I and 
2244–08II) were isolated from 2 patients (online Ap-
pendix Table, www.cdc.gov/EID/content/17/2/178-appT.
htm). During the period of screening, an increasing num-
ber of strains per year were registered. This increase 
could have been caused by the offi cial reporting system 
for STEC, which was initiated in Switzerland in 1999; or 
by a country-wide reporting program for HUS, which was 
initiated in Switzerland in 2004 and may have increased 
physician awareness for HUS.
Anamnestic Data
Anamnestic data for the 95 patients are shown in Fig-
ure 1. HUS developed in 38 patients (40%); 18 (47.4%) 
were male, 20 (52.6%) were female, and median age was 
<2 years (range <1–81 years). Bloody diarrhea was noted 
for 54 (56.8%) patients, nonbloody diarrhea for 22 (23.2%), 
and anemia for 16 (16.8%). For 7 patients, no anamnestic 
data were available. Ten (10.5%) patients were >60 years 
of age and 63 (66.3%) were <10 years of age. For some 
patients, there was epidemiologic evidence of contact with 
animals, traveling, or eating animal-derived food.
No data were available for use of antimicrobial drugs. 
However, it is generally assumed in Switzerland that no 
antimicrobial drugs should be given to patients with acute 
diarrhea if laboratory test results are not available.
Characterization of STEC Serotypes 
and Virulence Genes
The strains belonged to 40 O:H serotype; 4 serotypes 
(O26:H11/H–; O103:H2, O121:H19, and O145:H28/H–) 
accounted for 46.4% of the strains (online Appendix Ta-
ble). No signifi cant differences were found between most 
prevalent serogroups and symptoms observed.
When grown on sorbitol MacConkey agar, 80 (82.5%) 
strains fermented sorbitol and 17 (17.5%) did not. Forty-
fi ve (46.4%) strains had stx2 genes, 36 strains (37.1%) had 
stx1, and 16 (16.5%) strains had stx1 and stx2. Genes for 
enterohemolysin and intimin were detected in 75.3%, and 
70.1% of the strains, respectively.
PFGE Genotyping
PFGE conducted for strains of the most prevalent se-
rogroups (O26, O103, O121, and O145) showed that the 
patterns of O26 strains were heterogeneous (similarity co-
effi cient range 49%–94%) except for 5 strains (Figure 2). 
Patterns of O145 strains were also heterogeneous (similar-
ity coeffi cient range 56%–95%) except for 2 strains (Figure 
3). Patterns of O103 and O121 strains were heterogeneous 
(similarity coeffi cients ranges 86%–97% and 62%–91%, 
respectively) (Figures 4, 5). For O26 and O145 strains with 
the same PFGE patterns, no obvious epidemiologic link 
was observed between patients and different regions of 
Switzerland. Moreover, no information was available for 
about risk factors for these patients.
Antimicrobial Drug Susceptibility Testing
All non-O157 STEC strains were susceptible to 5 an-
timicrobial drugs (ceftazidime, ciprofl oxacin, cefotaxime, 
cefepime, and cefoxitin). Results are summarized in the 
online Appendix Table. Among 97 strains, 13 (13.4%) 
were resistant to ampicillin, 3 (3.1%) to amoxicillin/cla-
vulanic acid, 12 (12.4%) to cefalothin, 1 (1%) to cefpo-
doxime, 1 (1%) to cefuroxime, 2 (2.1%) to gentamicin, 
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and 21 (21.6%) to tetracycline. The most frequent com-
bination was resistance to ampicillin, cefalothin, and 
tetracycline, which was detected in 8 isolates, once each 
with additional resistance to amoxicillin/clavulanic acid 
or gentamicin. One strain, 1972–08, appeared to hyper-
express a broad-spectrum β-lactamase (resistance to am-
picillin, amoxicillin/clavulanic acid, cefalothin, cefuroxi-
me, and cefpodoxime).
Discussion
Over the 10-year study period (2000–2009), HUS 
caused by infection with non-O157 STEC was detected in 
38 (40%) of the 95 patients investigated. This frequency 
of HUS cases in our study was higher than that in other 
studies (10,11). In contrast to other studies, in which all 
diarrhea samples were screened for STEC, the set of non-
O157 strains in our study was isolated from patients with a 
reasonable clinical suspicion of infection with STEC. This 
fact could be the reason for a higher proportion of HUS and 
bloody diarrhea cases in our study group. Fourteen (36.8%) 
HUS cases were caused by STEC O26:H11; the remaining 
cases were caused by other serotypes. Of the patients with 
HUS, 20 (52.6%) were female and 18 (47.4%) were male. 
Furthermore, 30 (78.9%) were <5 years of age and only 4 
(10.5%) were >60 years of age.
In a study in Minnesota, USA, over a 7-year period 
(2000–2006) in which 108 non-O157 STEC isolates were 
obtained, HUS did not develop in any of the patients; 57% 
were female (10). In Germany, Austria, and Australia, O111 
strains were most frequently associated with HUS (11). In 
our study, 32 (84.2%) of the HUS isolates had stx2 as the 
only STEC gene (75%) or in combination with stx1 (25%), 
and 6 (15.8%) isolates had only stx1. This frequency of stx2 
in HUS isolates is similar to that in other countries, such as 
the United States (12).
Among the 30 detected STEC serogroups, O26 was 
most common (28 strains), followed by O145 (10 strains), 
O103, and O121 (6 strains each). These frequently found 
serogroups and others (O20, O113, O128, O146, O148, 
and O174) identifi ed in our strain collection have also been 
found in sheep and cattle in Switzerland (13,14).
Our fi nding that O26 isolates (28.9%) were the most 
common non-O157 STEC serogroup found in Switzerland 
is similar to fi ndings reported from Belgium, Germany, Ja-
pan, Spain, and the United States (15–19). Similar to other 
countries (16), in Switzerland, STEC O26:H11/H– also 
caused several HUS cases.
Of the remaining major O groups, O145 (6 isolates 
of O145:[H28] and 4 isolates of O145:H25/H–) was the 
second most common non-O157 serogroup isolated in 
this study (10.3% of all isolates). Eight O145 isolates had 
positive results for stx2, eae, and ehxA; 1 isolate that did 
not ferment sorbitol had positive results for stx1, eae, and 
ehxA; and 1 isolate that had positive results for stx1 and 
stx2 also had positive results for eae and ehxA. These strain 
characteristics are similar to those of isolates from Finland 
Figure 1. Anamnestic data for 
97 non-O157 Shiga toxin–
producing Escherichia coli 
(STEC) (black bar sections) 
and 44 O157 STEC (white bar 
sections) strains isolated from 
human patients, Switzerland, 
2000–2009. H, hemolytic uremic 
syndrome; B, bloody diarrhea; 
D, nonbloody diarrhea; A, 
anemia; N, no anamnestic data 
available.
Figure 2. Dendrogram of Shiga toxin–producing Escherichia coli 
O26 strains isolated from human patients, Switzerland, 2000–2009. 
stx, Shiga toxin gene; eae, intimin gene. Scale bar indicates degree 
of similarity (%).
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and Germany (20,21). Four of the O145 strains were as-
sociated with bloody diarrhea, and 5 were associated with 
HUS, which is similar to symptom distribution associated 
with STEC O145 reported by Karch et al. (18).
The third most common non-O157 STEC serotypes iso-
lated were O103:H2/H– (6 strains) and O121:H19 (6 strains). 
In contrast to fi ndings from Germany (19), none of the O103 
strains from Switzerland were associated with HUS.
Among the STEC O121:H19 group, all but 1 of the 
strains were motile, fermented sorbitol, and were stx2, eae, 
and ehxA positive; the 1 exception was ehxA negative. Four 
patients had bloody diarrhea and HUS developed in 2 pa-
tients. These fi ndings confi rm the results of Johnson et al. 
(11), which showed that strains of serogroup O26, O103, 
O121, and O145 are more likely to be associated with cases 
of HUS.
Although STEC O111 is one of the most common se-
rogroups in countries such as Germany, Austria, and Aus-
tralia and is often associated with HUS (11,22), we found 
only 2 O111:H– strains that had the H8 genotype. One of 
these strains had stx1, eae, ehxA, and the other strain had 
stx1, stx2, eae and ehxA.  The patients from whom these 2 
strains were isolated sought treatment for bloody diarrhea 
and HUS, respectively.
According to FoodNet 2009 (23), the most common 
non-O157 STEC serogroups in the United States are O26 
(28.9%), O103 (20.0%), and O111 (14.9%). The frequency 
of O26 (28.9% of all isolates) in the United States is the 
same as that in Switzerland. However, the frequencies of 
STEC O103 and O111 in the United States are higher than 
those in Switzerland (STEC O103, 6.2%; STEC O111, 
2.1%).
In Germany, STEC O91 (H14/H21) is currently the 
fourth most common STEC serogroup isolated (24). How-
ever, we have detected only 1 O91:H10, stx2-positive, eae- 
and ehxA-negative, sorbitol-fermenting strain in Switzer-
land during the past decade. This strain was isolated from 
a 60-year-old woman in whom HUS developed. STEC 
O91 isolates that express fl agellar antigen H10 have been 
detected in different countries, albeit at low frequencies 
(25–27). O91 is usually eae negative and the most common 
serogroup isolated from adult patients (25). Another eae-
negative serogroup is O117, which is often associated with 
travelers, mainly to Asia, Africa, and Cuba (28). We identi-
fi ed 3 (3.1%) O117:H7 strains that were stx1 positive and 
stx2, eae, and ehxA negative. This virulence pattern was 
identical to that for 20 STEC strains reported by Olesen et 
al. (28). One of our strains was associated with a patient 
who traveled to India, a country that has been reported as 
the origin of O117 infections (29). However, no informa-
tion was available regarding travel for the other 2 patients 
in our study from whom the O117:H7 stx1-positive, stx2-, 
eae-, and ehxA-negative strains were isolated. Two of these 
patients had bloody diarrhea, but no clinical data were 
available for the third patient.
To detect genetic similarities and epidemiologic re-
lationships among STEC strains, we performed PFGE on 
representatives of serogroups that occurred at high fre-
quencies. O26 PFGE patterns were heterogeneous except 
for 2 strain sets, which had 2 and 3 strains without any 
obvious epidemiologic relationship to each other. Set 1 
contained 2 stx1-positive, eae-positive strains isolated in 
2001 (KO 2163–01 and KO 2164–01) from an 80-year-old 
woman and a 2-year-old-boy, respectively, each of whom 
had bloody diarrhea. Set 2 contained 3 stx2-positive, eae-
positive strains isolated in 2002 and 2003 (KO 1103–02, 
KO 1995–02, and KO 964–03), from 3 female patients (1, 
2, and 41 years of age), all of whom had HUS and bloody 
diarrhea. However, no information for risk factors, such as 
contact with animals, traveling, or eating animal derived-
food, was available for these 5 patients.
PFGE patterns for O145 strains were also heteroge-
neous, except for 2 similar strains without any epidemio-
logic relationships to each other that were isolated in 2008 
(K 145:25–1550–08 and K 145:25–2208–08; both stx2 and 
eae positive, 1 from a 2-year-old girl who was treated for 
HUS, and 1 from a 1-year-old boy who had bloody diar-
rhea). However, no information for risk factors, such as 
contact with animals, traveling, or eating animal-derived 
food, was available for these 2 patients. PFGE patterns of 
O103 and O121 strains were the most heterogeneous; none 
of the strains had the same patterns.
Figure 3. Dendrogram of Shiga toxin–producing Escherichia coli 
O145 strains isolated from human patients, Switzerland, 2000–
2009. stx, Shiga toxin gene; eae, intimin gene. Scale bar indicates 
degree of similarity (%).
Figure 4. Dendrogram of Shiga toxin–producing Escherichia coli 
O103 strains isolated from human patients, Switzerland, 2000–
2009. stx, Shiga toxin gene; eae, intimin gene. Scale bar indicates 
degree of similarity (%). 
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The stx gene distribution among all 97 non-O157 
STEC isolates showed that 45 (46.4%) strains had only 
stx2, 36 (37.1%) had only stx1, and 16 (16.5%) had stx1 
and stx2. Studies from Spain (17) and Finland (20) showed 
a similar distribution of stx genes among non-O157 STEC 
isolates. These fi ndings are in contrast to those from the 
United States (Minnesota), in which non-O157 STEC 
strains generally showed a higher frequency of isolates that 
had stx1 (10).
The presence of the eae gene has been reported to have 
some predictive value for STEC seropathotypes that are as-
sociated with epidemic disease and consequently associ-
ated with severe disease such as bloody diarrhea and HUS 
(12,30,31). Therefore, we performed statistical analysis 
with multinomial regression and binary logistic regression 
for our data.
Strains associated with HUS, compared to those as-
sociated with bloody diarrhea, were more likely to harbor 
stx2 and eae, but the presence of only 1 of these virulence 
factors was not signifi cantly associated. In our study, of 29 
patients who provided eae-negative isolates, 17 had bloody 
diarrhea, 4 had bloody diarrhea and HUS, 4 had HUS, 1 
had nonbloody diarrhea, and 3 had no clinical data avail-
able. Strains from the 8 patients with HUS comprised a va-
riety of serogroups (O20, O82, O91, O148, O153, O181, 
and ONT); only 5 had the stx2 gene. In our study, 21.1% 
of isolates from HUS patients were eae negative. The 3 
eae-negative, stx2-negative strains had only stx1 or stx1 
and ehxA. Strains with such a pattern of virulence factors 
are notable because they are less likely to cause HUS than 
strains harboring stx2. However, these fi ndings are consis-
tent with epidemiologic data from other countries (19,27), 
which indicate that certain eae-negative STEC strains 
cause hemorrhagic diseases in humans. A report from the 
United States (Minnesota) indicated that non-O157 isolates 
that had only stx1 can cause severe illness (bloody diarrhea 
or HUS) (32).
Resistance to >1 of the 12 antimicrobial drugs tested 
was identifi ed in 25 (25.8%) non-O157 STEC strains. This 
fi nding is consistent with results for a study in Spain, in 
which 238 (41%) of 581 non-O157 STEC strains were re-
sistant to >1 of 26 antimicrobial drugs (33). In our study, 13 
(13.4%) of 97 strains were resistant to ampicillin, 3 (3.1%) 
to amoxicillin/clavulanic acid, 12 (12.4%) to cefalothin, 
1 (1%) to cefpodoxine, 1 (1%) to cefuroxime, 2 (2.1%) 
to gentamicin, and 21 (21.6%) to tetracycline. In STEC 
strains, the most frequent drug-resistance combination was 
resistance to ampicillin, cefalothin, and tetracycline, which 
was detected in 8 isolates, once with resistance to amoxicil-
lin/clavulanic acid and once with resistance to gentamicin. 
Comparably, Schroeder et al. (34) tested 137 non-O157 E. 
coli human isolates (including 37 STEC strains) from the 
United States, Saudi Arabia, Argentina, Canada, Mexico, 
Zambia, and Singapore and reported STEC drug-resistance 
frequencies of 14% for ampicillin, 5% for amoxicillin/cla-
vulanic acid, 11% for cefalothin, and 32% for tetracycline.
In conclusion, high genetic diversity within strains in-
dicates that non-O157 Shiga toxin–producing E. coli infec-
tions in Switzerland most often occurred as single cases. 
Because little data are available for clinical non-O157 
STEC infections in humans, our results may provide useful 
information for analysis of these strains.
Acknowledgments
We thank the Federal Offi ce of Public Health for support in 
obtaining anamnestic data, Grethe Sägesser for help with strain 
collection and technical support, and Paul Torgerson for statisti-
cal advice.
Ms Käppeli is a doctoral candidate at the Institute for Food 
Safety and Hygiene, Vetsuisse Faculty, University of Zurich. Her 
main research interest is characteristics of non-O157 Shiga toxin–
producing  E. coli.
References
  1.  The community summary report on trends and sources of zoonoses 
and zoonotic agents in the European Union in 2008. European Food 
Safety Authority Journal. 2010; 10:1496 [cited 2010 Nov 1]. http://
www.efsa.europa.eu/fr/scdocs/doc/s1496.pdf
  2.  Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga tox-
in–producing Escherichia coli infections. Clin Microbiol Rev. 
1998;11:450–79.
  3.  Beutin L, Miko A, Krause G, Pries K, Haby S, Steege K, et al. Iden-
tifi cation of human-pathogenic strains of Shiga toxin–producing 
Escherichia coli from food by a combination of serotyping and 
molecular typing of Shiga toxin genes. Appl Environ Microbiol. 
2007;73:4769–75. DOI: 10.1128/AEM.00873-07
  4.  Rüssmann H, Kothe E, Schmidt H, Franke S, Harmsen D, Caprioli A, 
et al. Genotyping of Shiga-like toxin genes in non-O157 Escherichia 
coli strains associated with haemolytic uraemic syndrome. J Med Mi-
crobiol. 1995;42:404–10. DOI: 10.1099/00222615-42-6-404
  5.  Piérard D, Muyldermans G, Moriau L, Stevens D, Lauwers S. 
Identifi cation of new verocytotoxin type 2 variant B-subunit genes 
in human and animal Escherichia coli isolates. J Clin Microbiol. 
1998;36:3317–22.
 6.  Schmidt H, Plaschke B, Franke S, Russmann H, Schwarzkopf A, 
Heesemann J, et al. Differentiation in virulence patterns of Escheri-
chia coli possessing eae genes. Med Microbiol Immunol (Berl). 
1994;183:23–31. DOI: 10.1007/BF00193628
Figure 5. Dendrogram of Shiga toxin–producing Escherichia coli 
O121 strains isolated from human patients, Switzerland, 2000–
2009 in Switzerland. stx, Shiga toxin gene; eae, intimin gene. Scale 
bar indicates degree of similarity (%).
Human Infections with Non-O157 STEC, Switzerland
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 2, February 2011 185 
  7.  Schmidt H, Beutin L, Karch H. Molecular analysis of the plasmid-
encoded hemolysin of Escherichia coli O157:H7 strain EDL 933. 
Infect Immun. 1995;63:1055–61.
  8.  Centers for Disease Control and Prevention. PulseNet [cited 2010 
Nov 2]. http://www.cdc.gov/pulsenet/
  9.  Clinical and Laboratory Standards Institute. Performance standards 
for antimicrobial disk and dilution susceptibility tests for bacteria 
isolated from animals; approved standard. 3rd ed. Wayne (PA): The 
Institute; 2008.
10.  Hedican EB, Medus C, Besser JM, Juni BA, Koziol B, Taylor C, et 
al. Characteristics of O157 versus non-O157 Shiga toxin–producing 
Escherichia coli infections in Minnesota, 2000–2006. Clin Infect 
Dis. 2009;49:358–64. DOI: 10.1086/600302
11.  Johnson KE, Thorpe CM, Sears CL. The emerging clinical impor-
tance of non-O157 Shiga toxin–producing Escherichia coli. Clin 
Infect Dis. 2006;43:1587–95. DOI: 10.1086/509573
12.  Brooks JT, Sowers EG, Wells JG, Greene KD, Griffi n PM, Hoekstra 
RM, et al. Non-O157 Shiga toxin–producing Escherichia coli infec-
tions in the United States, 1983–2002. J Infect Dis. 2005;192:1422–9. 
DOI: 10.1086/466536
13.  Zweifel C, Blanco JE, Blanco M, Blanco J, Stephan R. Serotypes 
and virulence genes of ovine non-O157 Shiga toxin–producing Es-
cherichia coli in Switzerland. Int J Food Microbiol. 2004;95:19–27. 
DOI: 10.1016/j.ijfoodmicro.2004.01.015
14.  Tasara T, Bielaszewska M, Nitzsche S, Karch H, Zweifel C, Stephan 
R. Activatable Shiga toxin 2d (Stx2d) in STEC strains isolated from 
cattle and sheep at slaughter. Vet Microbiol. 2008;131:199–204. 
DOI: 10.1016/j.vetmic.2008.03.001
15.  Bettelheim KA. The non-O157 Shiga-toxigenic (Verocytotoxigen-
ic) Escherichia coli; under-rated pathogens. Crit Rev Microbiol. 
2007;33:67–87. DOI: 10.1080/10408410601172172
16.  Bielaszewska M, Zhang W, Tarr PI, Sonntag AK, Karch H. Molecu-
lar profi ling and phenotype analysis of Escherichia coli O26:H11 and 
O26:NM: secular and geographic consistency of enterohemorrhagic 
and enteropathogenic isolates. J Clin Microbiol. 2005;43:4225–8. 
DOI: 10.1128/JCM.43.8.4225-4228.2005
17.  Blanco JE, Blanco M, Alonso MP, Mora A, Dahbi G, Coira MA, 
et al. Serotypes, virulence genes, and intimin types of Shiga toxin 
(verotoxin)–producing Escherichia coli isolates from human pa-
tients: prevalence in Lugo, Spain, from 1992 through 1999. J Clin 
Microbiol. 2004;42:311–9. DOI: 10.1128/JCM.42.1.311-319.2004
18.  Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia 
coli in human medicine. Int J Med Microbiol. 2005;295:405–18. 
DOI: 10.1016/j.ijmm.2005.06.009
19.  Mellmann A, Bielaszewska M, Köck R, Friedrich AW, Fruth A, 
Middendorf B, et al. Analysis of collection of hemolytic uremic 
syndrome–associated enterohemorrhagic Escherichia coli. Emerg 
Infect Dis. 2008;14:1287–90. DOI: 10.3201/eid1408.071082
20.  Eklund M, Scheutz F, Siitonen A. Clinical isolates of non-O157 
Shiga toxin–producing Escherichia coli: serotypes, virulence char-
acteristics, and molecular profi les of strains of the same serotype. 
J Clin Microbiol. 2001;39:2829–34. DOI: 10.1128/JCM.39.8.2829-
2834.2001
21.  Beutin L, Krause G, Zimmermann S, Kaulfuss S, Gleier K. Charac-
terization of Shiga toxin–producing Escherichia coli strains isolated 
from human patients in Germany over a 3-year period. J Clin Micro-
biol. 2004;42:1099–108. DOI: 10.1128/JCM.42.3.1099-1108.2004
22.  Schmidt H, Geitz C, Tarr PI, Frosch M, Karch H. Non-O157:H7 
pathogenic Shiga toxin–producing Escherichia coli: phenotypic and 
genetic profi ling of virulence traits and evidence for clonality. J In-
fect Dis. 1999;179:115–23. DOI: 10.1086/314537
23.  Centers for Disease Control and Prevention. FoodNet—Foodborne 
Active Surveillance Network [cited 2010 Nov 2]. http://www.cdc.
gov/foodnet/
24.  Werber D, Beutin L, Pichner R, Stark K, Fruth A. Shiga toxin–pro-
ducing Escherichia coli serogroups in food and patients, Germany. 
Emerg Infect Dis. 2008;14:1803–6. DOI: 10.3201/eid1411.080361
25.  Bielaszewska M, Stoewe F, Fruth A, Zhang W, Prager R, Brockmey-
er J, et al. Shiga toxin, cytolethal distending toxin, and hemolysin 
repertoires in clinical Escherichia coli O91 isolates. J Clin Micro-
biol. 2009;47:2061–6. DOI: 10.1128/JCM.00201-09
26.  Evans J, Wilson A, Willshaw GA, Cheasty T, Tompkins DS, Wheel-
er JG, et al. Vero cytotoxin–producing Escherichia coli in a study 
of infectious intestinal disease in England. Clin Microbiol Infect. 
2002;8:183–6. DOI: 10.1046/j.1469-0691.2002.00364.x
27.  Pradel N, Bertin Y, Martin C, Livrelli V. Molecular analysis of shiga 
toxin–producing Escherichia coli strains isolated from hemolytic–
uremic syndrome patients and dairy samples in France. Appl Envi-
ron Microbiol. 2008;74:2118–28. DOI: 10.1128/AEM.02688-07
28.  Olesen B, Jensen C, Olsen K, Fussing V, Gerner-Smidt P, Scheutz 
F. VTEC O117:K1:H7. A new clonal group of E. coli associated 
with persistent diarrhoea in Danish travellers. Scand J Infect Dis. 
2005;37:288–94. DOI: 10.1080/00365540410021090
29.  Vila J, Vargas M, Ruiz J, Gallardo F, Jimenez de Anta MT, Gascon 
J. Isolation of verotoxin-producing Escherichia coli O-rough:K1:H7 
from two patients with traveler’s diarrhea. J Clin Microbiol. 
1997;35:2279–82.
30.  Karmali MA, Mascarenhas M, Shen S, Ziebell K, Johnson S, Reid-
Smith R, et al. Association of genomic O island 122 of Escherichia 
coli EDL 933 with verocytotoxin-producing Escherichia coli se-
ropathotypes that are linked to epidemic and/or serious disease. J 
Clin Microbiol. 2003;41:4930–40. DOI: 10.1128/JCM.41.11.4930-
4940.2003
31.  Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, 
Gyles CL. Associations between virulence factors of Shiga toxin–
producing Escherichia coli and disease in humans. J Clin Microbiol. 
1999;37:497–503.
32.  Hedican EB, Medus C, Besser JM, Juni BA, Koziol B, Taylor C, et 
al. Characteristics of O157 versus non-O157 Shiga toxin–producing 
Escherichia coli infections in Minnesota, 2000–2006. Clin Infect 
Dis. 2009;49:358–64. DOI: 10.1086/600302
33.  Mora A, Blanco JE, Blanco M, Alonso MP, Dhabi G, Echeita A, et al. 
Antimicrobial resistance of Shiga toxin (verotoxin)–producing Es-
cherichia coli O157:H7 and non-O157 strains isolated from humans, 
cattle, sheep and food in Spain. Res Microbiol. 2005;156:793–806. 
DOI: 10.1016/j.resmic.2005.03.006
34.  Schroeder CM, Meng J, Zhao S, DebRoy C, Torcolini J, Zhao C, et 
al. Antimicrobial resistance of Escherichia coli O26, O103, O111, 
O128, and O145 from animals and humans. Emerg Infect Dis. 
2002;8:1409–14.
Address for correspondence: Roger Stephan, Institute for Food Safety 
and Hygiene, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 
272, CH-8057 Zurich, Switzerland; email: stephanr@fsafety.uzh.ch
All material published in Emerging Infectious Diseases is in 
the public domain and may be used and reprinted without 
special permission; proper citation, however, is required.
Use of trade names is for identifi cation only and does not 
imply endorsement by the Public Health Service or by the US 
Department of Health and Human Services.
